Sangamo showcases Fabry progress at WORLDSymposium™

Uncategorized

Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Showing Continued Tolerability and Sustained Elevated α-Gal A Enzyme Activity in Nine Patients

- Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation phase. - All nine patients exhibited elevated α-Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months